Balancing NET activity through targeted therapies—such as peptidyl arginine deiminase 4 (PAD4) inhibitors or deoxyribonuclease I (DNase I)—holds promise for treating ischemic stroke and other NET-related disorders. This evidence concerns the gene PADI4 and ischemic stroke.